Dalian Yalifeng Biopharmaceutical Begins Influenza A/H1N1 Vaccine Production
This article was originally published in PharmAsia News
Executive Summary
Dalian Yalifeng Biopharmaceutical has started to produce China's first batch of Influenza A/H1N1 vaccine. Upon receiving the H1N1 virus strain from WHO, the company has begun inoculation of chicken eggs for experiments. The vaccine production procedure will begin with virus amplification, followed by extraction of its surface antigen to produce the antibody. The first batch of six million doses is expected to be produced in Dalian by the end of September. The city's FDA will closely monitor the entire production process to ensure compliance with WHO standards. (Click here for more - Chinese Language)